POLYNITROXYL HEMOGLOBIN:NEUROPROTECTIVE OXYGEN CARRIER

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 1R43HL066887-01
Amount: $100,044.00
Phase: Phase I
Program: SBIR
Awards Year: 2001
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
1 TECHNOLOGY DR, E-309, IRVINE, CA, 92718
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 CARLETON HSIA
 () -
Business Contact
Phone: (714) 453-1072
Email: SYNZYME@SYNZYME.COM
Research Institution
N/A
Abstract
DESCRIPTION: (Investigator's abstract) Polynitroxyl hemoglobin (PNH) will be developed as a neuroprotective oxygen carrier. PNH is different from 1st generation hemoglobin-based oxygen carriers (HBOCs) in that it has added anti-inflammatory activity in addition to oxygen carrier function. PNH is created by covalently attached nitroxides, an analogue of nitric oxide (NO) in a piperdine "cage," to HBOC. We have shown that PNH is an oxygen carrier with anti-inflammatory superoxide dismutase and catalase mimetic activities. In the Phase I of the present application, we propose to develop PNH as an anti-inflammatory oxygen carrier and demonstrate that it is resistant to oxidative damage in vitro and neuroprotective in vivo. In Phase II of this SBIR application, we propose to elucidate the mechanisms and efficacy of PNH with a hemodilution protocol in clinically relevant brain injury models. In a companion Phase I/Il SBIR entitled "Polynitroxyl Hemoglobin (PNH) : Preclinical Safety," we propose to conduct toxicology studies of PNH for an IND submission to FDA. PROPOSED COMMERCIAL APPLICATION: An oxygen carrying resuscitative fluid with anit-inflammatory activities such as PNH is highly desirable. HBOC products in advanced clinical development, provide only oxygen delivery. Unfortunately, during severe hemorrhage, or trauma, there is significant inflammatory (ischemia and reperfusion) injury. The inflammatory injury often lead to multiple organ failure (MOF). Therefore the use of PNH is to provide better protection against MOF in trauma resuscitation and can be used as a neuroprotective oxygen carrier in ischemic, hemorrhagic and traumatic head injury. The market potential for a 2nd generation HBOC is established to be 3 billion/year.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government